Adial Pharmaceuticals, Inc. (ADIL)

NASDAQ: ADIL · IEX Real-Time Price · USD
1.21
+0.09 (8.04%)
Jun 29, 2022 12:10 PM EDT - Market open
8.04%
Market Cap 28.78M
Revenue (ttm) n/a
Net Income (ttm) -17.50M
Shares Out 23.79M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 215,213
Open 1.13
Previous Close 1.12
Day's Range 1.13 - 1.21
52-Week Range 1.04 - 5.08
Beta 0.83
Analysts Buy
Price Target 10.88 (+799.2%)
Earnings Date Aug 11, 2022

About ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. [Read more...]

Industry Pharmaceuticals
IPO Date Jul 30, 2018
Employees 16
Stock Exchange NASDAQ
Ticker Symbol ADIL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ADIL stock is "Buy." The 12-month stock price forecast is 10.88, which is an increase of 799.17% from the latest price.

Price Target
$10.88
(799.17% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley

CHARLOTTESVILLE, Va., June 28, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today issued the following letter to its shareholders from the Compa...

Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial

Expects Release of Top-Line Data in July Expects Release of Top-Line Data in July

Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Adial Pharmaceuticals, Inc. (ADIL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agre...

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company's Proprietary Genetic Diagnosti...

New patent covers the use of the full genetic panel measuring all five genetic biomarkers New patent covers the use of the full genetic panel measuring all five genetic biomarkers

Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate's A...

CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on dev...

Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter

Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate's Adenosine Compounds a...

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on dev...

5 Winning Stocks Backed by the Overlooked Rising P/E Strategy

Want to try an out-of-the-box approach? Tap five stocks (GIII, PPC, TAL, ADIL and CHS) with increasing P/E ratios.

Other symbols: CHSGIIITALPPC

Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim ...

CHARLOTTESVILLE, Va., March 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing th...

Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the T...

CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

Adial Pharmaceuticals Announces Closing of $10 Million Financing

CHARLOTTESVILLE, Va., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering

CHARLOTTESVILLE, Va., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5032 as a Potential Treatment for Asthma

CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced positi...

Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04

Patent covers patients with a specific genetic biomarker for the serotonin-3 receptor Patent covers patients with a specific genetic biomarker for the serotonin-3 receptor

Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.

Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 Conference

CHARLOTTESVILLE, Va., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share

CHARLOTTESVILLE, Va., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Compa...

CHARLOTTESVILLE, Va., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment an...

Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Ca...

PNV2 demonstrates reduction of metastases in animal model PNV2 demonstrates reduction of metastases in animal model

REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday, November 18, 2021 at 11:00AM Eastern to Provide Cli...

CHARLOTTESVILLE, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options

Financing to support clinical trial pathway for non-opioid drug candidate for treatment of pain Financing to support clinical trial pathway for non-opioid drug candidate for treatment of pain

Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments

CHARLOTTESVILLE, Va., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...

Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors

CHARLOTTESVILLE, Va., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment an...

Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate

Adial Pharmaceuticals Inc (NASDAQ: ADIL) has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound for its p...

Adial Announces Positive Pre-Clinical Data for Purnovate's PNV-5030 as a Drug Candidate for the Treatment of Pain

Results suggest potential of PNV-5030 as both a standalone and combination therapy  to reduce or eliminate opioid use and achieve meaningful pain reduction